Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities : pooled analysis of six prospective real-world studies including 11,999 patients

Alkhatib, Nimer; Sun, Diana; Denhaerynck, Kris; Hamarneh, Dina; Van Camp, Yoleen; Villa, Lorenzo; Brie, Heidi; Vancayzeele, Stefaan; MacDonald, Karen; Abraham, Ivo

doi:10.1080/03007995.2020.1853082

Title

Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities : pooled analysis of six prospective real-world studies including 11,999 patients

Author

Alkhatib, Nimer

Sun, Diana

Denhaerynck, Kris

Hamarneh, Dina

Van Camp, Yoleen

Villa, Lorenzo

Brie, Heidi

Vancayzeele, Stefaan

MacDonald, Karen

Abraham, Ivo

Abstract

Aims Six prospective real-world studies of antihypertensive treatment with valsartan-centric regimens were pooled to: (1) examine the effectiveness of similar to 90 days of second- or later-line valsartan treatment in hypertensive patients with known comorbidities; and (2) identify physician- and patient-related determinants associated with systolic (SBP) and diastolic blood pressure (DBP) outcomes in these patients. Methods and materials A pooled analysis was performed of an evaluable sample of 11,999 hypertensive patients with known comorbidities treated similar to 90 days with valsartan-centric regimens. We applied hierarchical linear and logistic regression models to identify determinants of blood pressure (BP) outcomes and a potential physician class effect. Results Valsartan regimens resulted in mean (SD) SBP and DBP reductions of 18.0 (15.8) mmHg and 9.5 (10.1) mmHg, respectively, at similar to 90 days, yielding SBP, DBP and combined SBP/DBP control rates of 44.0%, 67.2% and 39.3%, respectively. About a quarter of the variance in 90 day BP values was attributable to a physician class effect. BP outcomes declined with physicians' increasing years in practice and being male. At the patient level, BP outcomes declined with SBP and DBP at diagnosis; diabetes; higher cholesterol and BMI; lower valsartan and hydrochlorothiazide (HCTZ) doses; and concomitant anti-hypertensives. Older age was associated with improved DBP. A proxy of physician vigilance, cardiovascular disease history, was associated with improved BP outcomes, as were patient adherence and higher doses of valsartan in combination with HCTZ. Conclusions Valsartan-centric regimens have significant BP lowering benefits in this pooled sample of patients with known comorbidities. Many observed determinants of BP outcomes are modifiable or manageable.

Language

English

Source (journal)

Current medical research and opinion. - London

Publication

Abingdon : Taylor & francis ltd , 2021

ISSN

0300-7995

DOI

10.1080/03007995.2020.1853082

Volume/pages

37 :1 (2021) , 8 p.